Know Cancer

or
forgot password

Drug Use Investigation of Zevalin


N/A
N/A
N/A
Open (Enrolling)
Both
Non-Hodgkin's Lymphoma (NHL)

Thank you

Trial Information

Drug Use Investigation of Zevalin


Inclusion Criteria:



Patients who received Zevalin for relapsed or refractory:

- CD20+

- low grade B-cell non-Hodgkin's lymphoma

- Mantle cell lymphoma

Exclusion Criteria:

- Patients who are contraindicated based on the product label

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Incidence of adverse drug reactions in subjects who received Zevalin

Outcome Time Frame:

After In-111 Zevalin administration, up to 13 weeks

Safety Issue:

Yes

Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:

Bayer

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

15042

NCT ID:

NCT01448928

Start Date:

September 2008

Completion Date:

January 2018

Related Keywords:

  • Non-Hodgkin's Lymphoma (NHL)
  • Zevalin
  • CD20+
  • Non-Hodgkin's Lymphoma
  • Mantle Cell Lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location